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INTRODUCTION 
HISTORY OF MULTIPLE SCLEROSIS 
 
The first multiple sclerosis (MS) case was described in 14th century in a 16 
years-old girl with ambulation difficulties, headache and teethache. The young 
girl was known later as Santa Ludwina of Schiedam (130-1433) (Maeder R, 
1979). At the age of 19 Ludwina suffered of eye blindness and was bed-bound. 
Ludwina’s disease went on with progression even if with remission periods 
during which she was able to walk with assistance, until her death at 53 yers. 
To find a second case of MS in history we need to wait the 19 century with the 
appearance on the scene of Sir August d’Este. He was the outlawed son of 
George the third, king of England. Sir August told about his disease in his diary. 
Retrospectively diagnosed as MS, the disease started at 26 year-old with 
several episode of optic neuritis. In 1822 he was sent to Driburg for thermal 
treatment where his symptoms went back. His diary contains enough 
informations to ensure he was affected by a relapsing-remitting form of MS, 
characterized by vision loss, diplopia, sensory impairment and bladder 
dysfunction. 
The first description of MS lesions came from Robert Carswell (1793-1857) 
Atlas of Pathology, published in 1838. Carswell wrote: “… a peculiar 
pathological status of spinal cord and pons, associated to atrophy”. However, it 
was only with Jean-Martin Charcot (1825-1893), a french neurologist, that the 
correlation between MS symptoms and pathological changes on autoptic 
samples was established. Charcot named the condition “sclerose en plaque”. 
Moreover, Charcot was the father of the first diagnostic criteria for MS called 
Charcot triade: diplopia, ataxia and disartrya. Lastly, he provide a full 
histological description of lesions pointing out myelin loss and glial activation. At 
the beginning of 20th century Professor Denny-Brown observed that a damaged 
nerve, when stimulated, was nomore able to conduct stimulus to muscles. He 
concluded that demyelinated plaques were reason for conduction blocks in 
nerves and consequently in spine and brain. 
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Epidemiology of multiple sclerosis. 
To date, we know that MS is an acquired immunomediated and inflammatory 
disease, characterized by inflammation, demyelination and primary and 
secondary axon degeneration (Pugliatti M, 2006). Data supporting the 
autoimmune theory are: (1) women are more affected as in other autoimmune 
diseases; (2) relatively steadiness of the disease during pregnancy; (3) frequent 
association with other autoimmune diseases and their presence in the 
parenthood; (4) association with type II HLA; (5) similarities with experimental 
allergic encephalomyelitis, used as a model for MS; (6) presence in serum and 
cerebro spinal fluid (CSF) of auto-antibodies against myelin’s antigens (Marrie 
RA, 2004). 
MS affects about 1.000.000 people between 17 and 65 years-old in the whole 
world. In 2000 MS prevalence rate in the white american population was around 
191 cases per 100.000 inhabitants and the incidence rate was 7.3 per 100.000 
years-person (Mayr WT, 2003). MS is twice as common in women as in men; 
men usually tend to have a later onset and a worse prognosis, probably 
depending on gender-associated factors on phenotypic and aetiological 
variability. 
In Europe, mean prevalence rate is higher in northern countries, depending on 
better quality of diagnostic process, although great variability in the same area 
(Scotland, north Norway). Prevalence rates varies between 11 and 282 per 
100.000 in women and between 10 and 123 in men, with a female:male rate  
between 1.1 and 3.4. 
The highest prevalence rate has been noticed in age between 35 and 49 in all 
nations with the exception of Ireland, Great Britain and Norway, where the 
disease as a major prevalence in the 50 – 64 age group. Mean incidence rate in 
Europe is 4 cases per 100.000/year (Pugliatti M, 2006). Mortality rate in Europe 
stays in a range between 0.5 and 3.6 per 100.000. 
In Italy prevalence rate for mainland is between 40 and 70 per 100.000 
inhabitants (Malatesta G, 1991; Meucci G, 1992; Granieri E, 1996; Maddestra 
M, 1998; Totaro R, 2000), with the only exception of Salerno (35 per 100.000 in 
1998) (Iuliano G, 1999) and Valle d’Aosta with 90 cases over 100.000 
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inhabitants (Sironi L, 1997). Female:Male rate varies between 1.2 and 2.3 and 
the higher prevalence rate has been found in age 35-49 years old, both in 
hinterland and Islands. The increase in prevalence and incidence across years 
can be ascribed to a better accuracy in diagnosis. (Granieri E, 1996).  
 
Natural History of multiple sclerosis 
MS is an autoimmune inflammatory disease affecting the CNS, which implies 
acute axonal damage caused by inflammation, mechanisms of functional and 
structural recovery and neurodegeneration. Primary target of inflammation is 
myelin, a protein involved in isolation of axons necessary for saltatory 
conduction. Consequences of demyelination may explain clinical and laboratory 
findings in MS. Partially demyelinated axons have a slower conduction giving a 
delay in evoked potentials. Demyelinated axons present spontaneous 
depolarisations and have a higher excitability, explaining symptoms as 
phosphenes and Lhermitte sign.  Close demyelinated axons may cross-react 
and give rise to paroxysmal symptoms, such as trigeminal neuralgia (Compston 
A, 2002). 
Symptoms and signs of MS poorly reflects the functional anatomy of 
demyelinated axons. Usually brain is involved, mostly when assessed by MRI. 
Lesions located in brainstem and cerebellum are more precisely related to 
specific symptoms. Spinal cord too is frequently affected by demyelinating 
lesions. 
Since there are no single clinical or laboratory variables which can detect MS, 
diagnostic criteria were developed as combination of clinical and paraclinical 
data, since Schumacher Criteria were proposed (Schumacher FA, 1965). 
Afterwards, in 1982, diagnostic pathway has been modified introducing different 
degrees of certainty: clinically defined MS, defined MS with laboratoristic 
support, probable MS with laboratoristic support (Poser CM, 1983). In July 2000 
the International Panel on the Diagnosis of MS has been instituted, with the aim 
of introducing diagnostic criteria for clinical practice and clinical trials (McDonald 
WI, 2001), which have been revised in 2005 (Polman CH, 2005).Moreover, MRI 
parameters and criteria for primary progressive MS (Thompson AJ, 2000) 
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(characterized by the absence of relapses and remission phases) were included 
in the diagnostic chart (Fig.1). 
 
Figure 1. Diagnostic Criteria (McDonald 2001) with clinical and paraclinical variables. MRI= 
Magnetic Resonance Imaging; CSF= Cerebro-spinal Fluid; VEP= Visual Evoked Potentials. 
 
The basis for the current diagnostic criteria (Tab. 1) is: 
1. To have objective evidence for dissemination in time and space; 
2. Clinical evidence with objective clinical sign. Diagnosis of MS based on 
clinical history may be possible if there is evidence of dissemination in 
time and space of lesions; 
3. Laboratoristic and radiological tests, such as CSF analysis, visual 
evoked potentials (VEP) and mostly MRI, may support diagnosis if 
clinical evidence confirms at least one objective lesion; 
4. A subject may be diagnosed as having MS or not having MS. A patients 
with a disease onset suggestive of MS but with unsatisfactory clinical and 
instrumental evaluation may be considered as affected by “possible MS”. 
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Table 1. The 2005 Revision to the McDonald Criteria for Multiple Sclerosis. 
 
In the diagnostic panel is a terminology deserving a precise definition in 
order to understand its importance for a correct diagnosis. 
a. Definition of “attack”: synonymous for relapse, it is the acute onset of 
neurological symptoms consistent with MS, in case of clinical evidence that 
causative lesions have an inflammatory and demyelinating nature. An attack 
has to last at least 24 hours (Poser CM, 1983). Although medical history may 
suggest an attack, diagnosis need to be supported by noticing clinical 
objectivation of at least one lesion. Moreover, a second event has to occur at 
least 30 days after a first event. 
b. CSF analysis: CSF analysis gives evidence of the inflammatory nature of 
lesions, useful when MRI criteria are not fully satisfied. CSF analysis is 
considered abnormal if IgG oligoclonal bands are detected in the absence of 
corresponding bands in serum(Andersson M, 1994), and/or Link index is 
elevated (Link H, 1977). CSF analysis does not provide informations on time 
and space dissemination of lesions and attacks. 
c. Visual Evoked Potentials: VEP are considered suggestive of demyelination 
in case of increased latency with normal amplitude and morphology (Halliday 
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AM, 1993); they may support the diagnosis to give objectivation of a clinical 
apparent or asymptomatic lesion of the visual system (Gronseth GS, 2000).  
d. MRI: brain and spinal lesion give evidence of dissemination in time and 
space. The international study group has adopted Barkhof and Tintorè 
diagnostic criteria (Barkhof F, 1997; Tintorè M, 2000), because of higher 
specificity and accuracy compared to previous studies by Fazekas et al 
(Fazekas F, 1988) and Paty et al (Paty DW, 1988). Barkhof’s Criteria 
required the presence of at least 3 of subsequent 4 items: 1) one lesion with 
enhancement after gadolinium or 9 T2-hyperintense lesions if no 
enhancement noticed; 2) at least 1 infra-tentorial lesion; 3) at least 1 
juxtacortical lesion (U fibers involved); 4) at least 3 periventricular lesion 
(Table 2). Lesions are considered if larger than 3 mm; moreover, a spinal 
cord lesion may replace a brain lesion (Mc Donald WI, 2001). In the 2005 
revision of diagnostic criteria, the International Panel reached a consensus 
on spinal cord lesions importance: 
1. Spinal cord MRI is a useful tool in differential diagnosis. Whether 
lesions have been detected in healthy subjects brain, nor have been 
in healthy spine (Kidd D, 1993; Bot JCJ, 2002; Lycklama G, 2003). 
2. Lesions of spinal cord suggestive of MS (no oedema; T2-
hyperintense areas in spinal cord; at least 3 mm in diameter, but 
shorter than 2 segments; less than half transversal spinal cord 
involvement) are useful for diagnosis if space dissemination lacks 
(Dalton CM, 2003; Bot JCJ, 2004; Brex P, 1999). 
3. For dissemination in space, one spinal lesion is equal to a brain 
lesion; a spinal lesion enhancing after gadolinium administration is 
equal to a brain enhancing lesion and can be considered twice (a 
single spine enhancing lesion is equivalent to a brain enhancing 
lesion plus an infratentorial brain lesion). Moreover, a spine lesion 
may contribute with brain lesions to reach the 9 T2-depending lesions 
required by Barkhof Criteria (Table 2). 
4. Spinal lesion should be focal and well defined in T2 sequences to 
be considered in MS diagnosis.  
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5. Serial spine MRI when there is no evidence of symptomatic 
myelitis is not useful for dissemination in time (Dalton CM, 2003). This 
tool is only a support for MS diagnosis when spine involvement is 
clinically suspected. 
 
 
McDonald Criteria published in 2001 consider both enhancing lesions and 
new T2 lesions for time dissemination. In 2005, a revision of diagnostic 
criteria confirmed the utility of T2 lesions for time dissemination also if 
appearing earlier than 3 months after a previous scan as required in 2001 
Criteris (Tab. 3). However, new T2 lesions in the first weeks after onset 
can not be considered a new and independent event. New MRI T2 lesions 
have to occur at least after 1 month from disease onset. Therefore any 
new T2 lesion detected in whatever follow-up scan compared to a 
reference one done at least 1 month from onset, can satisfy MR criteria for 
dissemination in time (Table 3).  
 
Tabella 3. MRI diagnostic criteria for Time dissemination. 
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In 2010 a new revision of diagnostic criteria (Polman et al, 2010) introduced the 
opportunity to demonstrate time dissemination with a single MRI scan (1 
gadolinium enhancing lesion plus 1 or more non-enhancing lesions). In the new 
Criteria to demonstrate dissemination in space at least 1 lesion in two different 
areas (periventricular, juxtacortical, spinal cord, infratentorial) are required. 
In MS differential diagnosis many medical conditions have to be considered. In 
young adults one has to consider vascular diseases, such as antifosfolipides 
syndrome, systemic ehritematousus lupus (SEL), cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 
Takayasu disease. Some infectious diseases as Human T-lymphotropic virus 
Type I infection and Lyme disease may present t onset like MS. Monophasic 
demyelinating disease, as acute demyelinated encephalomyelitis, Devic 
syndrome (Wingerchuk DM, 1999) and transverse myelitis represent a 
diagnostic challenge.  
MS may present in different forms with great variability in disability accrual. MS 
course is expression of two clinical phenomena: recurrence of neurological 
symptoms (acute onset of neurological impairment with complete or partial 
recovery) and progression (irreversible symptoms worsening lasting more than 
3 months). Relapses are clinical manifestation of focal and recurrent 
inflammation in CNS (Youl BD, 1991). Several pathological (Evangelou N, 
2000) and imaging (Losseff NA, 1996; Arnold DL, 1999; Ciccarelli O, 2001; 
Filippi M, 2003) studies have demonstrated that progression and disability are 
related to early and progressive axonal loss, meaning degenerative processes. 
In about 85% of MS patients, relapses are the only expression of disease in the 
first years, defining the relapsing-remitting course of MS. A percentage of these 
patients, increasing proportionally with disease duration, the course changes 
toward secondary progression. Fifteen percent of patients have a primary 
progressive onset. Relapses affected 40% of patients in primary and secondary 
progressive phases (Confavreux C, 2000, 2006). 
Currently, four different disease course are recognised, according to Lublin e 
Reingold, 1996 (Fig.2). The most common course is the one defined as 
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relapsing-remitting (RR), with 
recurrence of neurological 
symptoms and signs. The 
secondary progressive (SP) course 
follow a RR disease, evolving in 
chronic progression with or without 
superimposed relapses. Primary 
progressive (PP) MS is defined 
when progression of symptoms is 
present t onset without relapses 
during time. Progressive relapsing 
(PR) MS replicate PP MS, but 
shows relapses in time. In addition, 
few author have introduced the 
definition of transitional MS to indicate MS patients with an isolated relapse 
before or after progression (Filippi M, 2005). From population study Lyon 
Multiple Sclerosis Cohort we have learned that in RR MS there is an higher 
proportion of female patients (F=68%; M=61%) compared to secondary 
progressive MS. However, RR and SP MS share age at onset of RR phase, 
symptoms at onset, recovery from onset and remission duration between first 
and second attack. Otherwise, disease duration resulted almost double in the 
secondary progressive group (Confavreaux C, 2006). This is in line with the well 
known phenomenon, that sees a growing proportion of patients with an initial 
RR disease course will linearly convert to secondary progression over time 
(McAlpine D and Compston ND, 1952; Confavreux C, 1977; Wukusic S and 
Confavreux C, 2003). Conversion rate to secondary progressive course is about 
2-3% per year (Wukusic S and Confavreaux C, 2003), with a median time to 
progression of 19 years (Amato MP, 2000).  
Observational data collected in MS natural history studies suggest that disease 
phenotype and course are age-depending. 
Positive prognostic factors are visual and sensory symptoms at onset and 
complete recovery of relapses. On the contrary, motor involvement has a 
Figure 2. MS disease course. 
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negative prognostic value. Quoad Vitam prognosis is worse if MS affects aged 
male. Even a high relapse rate with poor recovery and a short time between 
onset and second attack are considered negative prognostic factors 
(Weinshenker BG, 1989). However, the factor that influence disability the most 
is the beginning of progressive phase.  
MS patients accumulate disability through 2 different mechanisms: partial 
recovery after relapses and disease progression. RRMS patients accumulate 
disability slower compared to PP patients, from the onset. Anyway, after a 
disability limiting the patients to walk less than 500 meters (equal to EDSS 4.0), 
the following disability does not correlate anymore with disease presentation 
(Confavreux C, 2000). 
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DEFINITION OF FATIGUE 
Fatigue has both central and peripheral components, whose relative 
contribution to fatigue appears to be task dependent (Enoka RM, 1992). Central 
fatigue refers to an activity-induced inability to fully activate a muscle voluntarily. 
Peripheral fatigue implies that the ability of the muscle to produce force is 
reduced. 
During sustained muscle actions, central and peripheral fatigue have been 
described to develop during maximal (Bigland-Ritchie B, 1983), as well as 
submaximal (Losher WN, 1996), voluntary efforts. During intermittent muscle 
actions, both central and peripheral fatigue develop when the effort is maximal 
(Taylor JL, 2000), whereas, when the effort is submaximal fatigue has been 
shown to be caused mainly by peripheral mechanisms (Bigland-Ritchie B, 
1986). Commonly discussed factors that affect peripheral fatigue include energy 
supply (Sahlin K, 1998), muscle fiber-type distribution (Tesch P, 1978; 
Thorstensson A, 1976), muscle strength before fatigue (Hunter SK, 2003; 
Kanehisa H, 1997), and the length of the muscle (Fitch S, 1985). Possible 
mechanisms of central fatigue are suboptimal facilitation from the motor cortex 
(Taylor JL, 2000), decreased facilitation from muscle spindles (Macefield G, 
1991), increased inhibition from group III and IV afferents (Garland SJ, 1991-
1995), and desensitization of the motorneurons (Kernell D, 1969). Moreover, 
the ability of the central nervous system to fully activate a muscle during 
maximal efforts has been described to vary substantially between muscle 
groups, muscle action types, and individuals (Behm DG, 2002; Loscher WN, 
2002; Westing SH, 1991).  
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FATIGUE IN MULTIPLE SCLEROSIS 
Fatigue is an overwhelming sense of tiredness, lack of energy and feeling of 
exhaustion, which affects up to 80% of patients with MS and impacts 
significantly their quality of life (Fisk et al., 1994). It interferes with work, family 
life and social activities (Kos et al., 2008). Fatigue, as a subjective and non-
specific symptom, can be often confused with weakness and/or depressed 
mood. Usually fatigue is present even at rest and it is worse in the second part 
of the day. Fatigue has not to be mistaken with fatigability, which is a 
generalised sense of exhaustion affecting patients after few minutes of physical 
activity, not present at or after rest. Fatigue may occur at any stage of MS, and 
affects even patients with mild disease course (Krupp et al.,1989). In some 
occasions, fatigue may be the first symptom of the disease, preceding of weeks 
or months the first disease episode. Fatigue is often present in patients as a 
chronic condition. However, some MS patients may experience transient fatigue 
because of external factors (i.e. exercise, disease-modifying therapy, 
temperature increase, etc). Fatigue in MS has not been clearly associated with 
disability (Schwartz et al., 1996). 
Fatigue can be divided in peripheral, central and mental fatigue. Peripheral 
fatigue is generated by loss of force-generating energy within the muscles. 
Central fatigue is due to inability to sustain the central drive to spinal neurons. 
Mental fatigue is a reduction in cognitive performance affecting mostly memory 
and abstract thought. In multiple sclerosis, fatigue is supposed to be of central 
(supraspinal) origin, as demonstrated by interpolated transcranial magnetic 
stimuli during voluntary effort (Lee et al., 2008) and by the reduction of 
intracortical inhibition, pre- and post-exercise, in fatigued patients (Liepert et al., 
2005). Fatigue in MS is likely to be due, at least in part, to presence of 
conduction block in demyelinated axons (Steve at al., 2010). This hypothesis 
was supported by an electroencephalographic study showing an increase in 
cortical activation and reduced cortical inhibition during a simple motor task in 
fatigued MS patients (Leocani et al., 2001). 
Some 40 to 70 percent of individuals with MS who experience fatigue do so on 
a daily basis, typically up to 6 hours, usually in the afternoon (Freal et al., 1984; 
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Fisk et al., 1994). Longitudinal studies suggested that people with MS who have 
severe fatigue do not experience significant spontaneous improvement of 
fatigue over intervals as long as 2 years (Cookfair et al., 1997). This is in 
contrast to individuals who do not have MS, whose fatigue fluctuates 
significantly over intervals as short as 2 weeks (Vercoulen et al., 1996a). Krupp 
et al. (Krupp et al., 1988) systematically defined the following characteristics 
that distinguished fatigue in MS from normal fatigue: 
•It comes on easily. 
•It prevents sustained physical functioning.  
•It is worsened by heat. 
•It interferes with responsibilities. 
•It interferes with physical functioning. 
•It causes frequent problems. 
Features that did not distinguish fatigue in individuals with MS from those 
without MS are worsening of fatigue associated with exercise, stress, 
depression, prolonged physical activity, and time of day (afternoons), and 
improvement of fatigue with rest, sleep, positive experiences, and sex. 
At any point in time, the percentage of people with chronic fatigue in general 
practices ranges from 24 to 37 percent; almost 70% of these cases presumably 
are due to medical and psychiatric conditions (Bates et al., 1993; Kroenke et al., 
1988; Buchwald et al., 1987). Although the prevalence of comorbid medical 
conditions associated with fatigue has not been evaluated in MS populations, 
MS patients are subject to all the common conditions associated with fatigue 
and require thorough evaluation before clinicians assume that fatigue is caused 
primarily by MS. Common comorbid medical conditions associated with fatigue 
include infectious diseases, anaemia, hypo- or hyperthyroidism, cardiovascular 
disease, pulmonary disease, renal disease, and hepatic disease.  
Empirical literature on the relationship between stress, coping, and anxiety and 
fatigue is poor. Few studies address the relationship between depression and 
fatigue. Prevalence estimated of the rate of depression among persons with MS 
range from 14 to 57 percent (Joffe et al., 1987; Whitlock and Siskind, 1980), 
 15 
while estimated of lifetime prevalence range from 37 to 54 percent (Minden et 
al., 1987; Schiffer et al., 1983).  
Clark et al. reported disrupted sleep in 25 to 35 percent of patients with MS 
(Clark et al., 1992). Common causes were neurogenic bladder dysfunction, 
spasticity, spasms, anxiety, depression and pain (Clark et al., 1992). Less 
commonly, the aetiology is a primary sleep disorder such as sleep apnoea or 
periodic leg movements, but limited evidence suggests that the frequency of 
these disorders in MS is still much greater than in control populations (Ferini-
Strambi et al., 1994). Though, it is reasonable to imagine a relationship between 
disrupted sleep disorders and fatigue, but studies have had mixed results. A 
challenge to distinguish daytime complaints of fatigue from excessive daytime 
sleepiness related to primary or secondary sleep disorders. Tiredness, fatigue, 
and sleepiness are considered similar symptoms by many patients. However, 
no study has directly evaluated the benefits of improved sleep on daytime 
fatigue.  
 
PRIMARY MS FATIGUE 
Studies that tried to identify the component of fatigue directly related to the 
MS disease process (primary fatigue) have investigated characteristics of MS 
associated with fatigue severity. A clinical trial of interferon-beta 1a in mild 
relapsing remitting MS showed a correlation between FSS scores and EDSS 
scores at baseline and at week 104 (Cookfair et al., 1997). Correlations 
between EDSS and FSS remained after adjusting for Beck Depression 
Inventory scale. The majority of low disability patients with MS (EDSS range of 
1–3.5) reported severe fatigue; almost 60 percent had FSS scores of 5.0 at 
baseline (FSS range of 1–7). Only persons with baseline FSS scores < 5.0 
showed a worsening in FSS score by week 104 (37 percent of study 
participants). The majority of participants showed stable and persistent levels of 
fatigue over the 104 weeks of the study. This ceiling effect of self-reported 
fatigue severity in individuals even mildly affected may be responsible for the 
observation in previous small cross-sectional studies reporting little or no 
correlation between fatigue severity and disability. The results of the Cookfair 
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study (1997) confirm the high prevalence of severe fatigue in even mildly 
disabled individuals with MS. This finding is in agreement with previous studies 
in which one-third to one-half of patients with MS reported fatigue precedes the 
onset of other symptoms of MS, even by years (Krupp et al., 1988; Fisk et al, 
1994). The appearance of fatigue prior to other symptoms of MS may be 
directly related to MS disease process, since approximately one-third to one-
half of patients presenting with their first identifiable symptoms of MS (i.e., optic 
neuritis, transverse myelitis) have disseminated white matter lesions at MRI that 
must have been present for some time prior to diagnosis (Morissey et al., 1993; 
Beck et al., 1993). The finding that FSS scores did not correlate with T2 lesion 
burden in the Cookfair et al. study does not take away attention from this 
hypothesis, because a study on the association of frontal lobe and basal ganglia 
hypometabolism with fatigue in MS also did not find any correlation between 
MRI abnormalities and fatigue (Roelcke et al., 1997). Despite the known 
association between MS disease process and fatigue, the pathophysiologic 
mechanisms resulting in the subjective sense of fatigue are still unclear. Four 
hypothetical sources of this fatigue has been identified. First, evidence from 
event-related potential recordings during auditory memory tasks suggests an 
impairment between stimulus evaluation and activation of motor programs 
(Sandroni et al., 1992). This is consistent with the observation of frontal lobe 
hypometabolism in fatigued individuals with MS (Roelcke et al., 1997) and could 
account for cortical component of fatigue. The mechanism of this cortical 
impairment is unknown, but could involve conduction block involving 
intracortical circuits. Second, fatigue could be a manifestation of intermittent 
conduction block in partially demyelinated axons of central motor pathways (Fig. 
3). Current evidence supports a cortical component to the subjective sense of 
fatigue, since some studies were unable to substantiate this hypothesis 
(Sheean et al., 1997).  
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Figure 3. Possible mechanism of central origine of fatigue. 
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In a myelinated axon, action potentials are generated at the node of Ranvier by 
transient ‘‘opening” of voltage-gated sodium channels, thereby resulting in an 
influx of sodium ions, termed ionic current, and membrane depolarization. This 
influx of sodium ions sets up a driving current that excites the subsequent node 
to threshold, resulting in opening of more voltage-gated sodium channels and 
ultimately axonal conduction. The process by which an action potential is 
propagated or ‘‘jumps” from one node of Ranvier to the next is referred to as 
saltatory conduction. Different channels are distributed unevenly along the 
axonal membrane: two classes of sodium channels are found in high 
concentrations at the node, including voltage-gated sodium channels as well as 
persistent Na+ channels. Slow potassium channels are also present at the node 
as well as in the internode. Fast potassium channels are almost exclusively 
located in the juxta-paranode and are a redistributed to the node in 
demyelinated axons thereby interfering with impulse conduction and 
contributing to conduction failure. Inward rectifier channels are permeable to 
both potassium and sodium ions and act to limit the extent of axonal 
hyperpolarization, whereas the electrogenic sodium/potassium pump serves to 
reverse ionic fluxes that may be generated through activity. In demyelinated 
axons, the safety factor of transmission is reduced thereby resulting in either 
hyperpolarizing or depolarizing conduction block. Dysfunction of sodium/ 
potassium pump, recently reported in multiple sclerosis, results in increased 
intra-axonal sodium levels, which in turn causes reverse operation of the 
sodium–calcium exchanger, an increase in intraxonal calcium concentration and 
ultimately axonal degeneration. 
Third, recruitment of alpha motor neurons is impaired because of corticospinal 
tract involvement and could result in increased energy demands for muscle 
activation (Rice et al., 1992). Lastly, abnormal co-activation of agonists and 
antagonists associated with spasticity could increase energy demands (Olgiati 
et al., 1988).  
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SECONDARY MS FATIGUE 
Fatigue in MS may also be secondary to disease mechanism. Three elements 
are involved in secondary MS fatigue: deconditioning, respiratory muscles 
weakness and pain. 
Deconditioning. Although MS is strictly a disease of the CNS, peripheral 
sources of fatigue could involve a number of mechanisms. Many studies 
suggested an intramuscular component to fatigue in MS (Miller et al., 1990; 
Kent-Braun et al., 1994; Sharma et al., 1995). Authors founded a relationship 
between the impaired muscle fatigue and the Ashworth score of spasticity and 
foot tapping rates, suggesting changes in muscle secondary to upper motor 
neuron impairment. However, the researchers were not able to correlate muscle 
fatigue with an individual’s subjective sense of fatigue. These results suggest 
that aerobic exercise and strengthening may be important to prevent secondary 
changes in muscle due, in part, to deconditioning. 
Respiratory Muscle Weakness. Another potential peripheral source of fatigue is 
respiratory muscle weakness. Even patients with low disabiity may demonstrate 
a reduced exercise capacity at least partially due to inspiratory or expiratory 
muscle fatigue (Foglio et al., 1994). As the disease progresses and patients 
become wheelchair-bound, respiratory muscle weakness may become an 
important factor of peripheral fatigue and may also result in significant sleep 
disruption (Smeltzer et al., 1996). The contribution of deconditioning to 
respiratory muscle weakness and the potential improvements in respiratory 
muscle function with exercise and expiratory training need to be confirmed in 
further studies. No studies have attempted to link subjective fatigue with 
respiratory muscle weakness in MS patients. 
Pain. The relationship between pain and MS fatigue has not been clarified. 
About 40 to 53 percent of people with MS experience chronic pain, often ill-
defined in aetiology (Moulin et al., 1988; Warnell, 1991; Archibald et al., 1994). 
Of interest is the common association of chronic widespread or regional pain, 
sleep disturbance, and fatigue in MS (Warnell, 1991; Archibald et al., 1994). 
Fatigue is influenced by physical, social, cultural, and institutional environment. 
However, the evidence for these relationships is almost nonexistent. One 
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exception is the effect of elevations in core and ambient temperature on 
neurological function and fatigue, a subject reviewed by Syndulko et al. (1996). 
Many authors published observations and controlled studies of heating 
reactions since Uhthoff’s initial report in 1890 estimated the incidence of heat 
sensitivity in individuals with MS to be between 60 percent and 80 percent. A 
similar incidence of heat-related worsening of MS fatigue was documented in 
two studies (Freal et al., 1984; Krupp et al., 1988). Moreover, this phenomenon 
can be observed with core temperature elevations as little as 0.5°F (i.e., normal 
diurnal temperature fluctuations). Therefore, heat sensitivity must be considered 
as a dimension of fatigue during everyday activities of daily living as well as 
during the heat waves of summer. The mechanisms by which heat may worsen 
neurological signs and symptoms in MS remain still unclear. Presumably, the 
enhanced susceptibility of demyelinated axons to conduction block with 
elevations in temperature plays an important role in this phenomenon (Davis 
and Jacobson, 1971; Rasminsky, 1973). 
 
MAGNETIC RESONACE IN MS WITH FATIGUE 
Conventional MRI studies, based on T1 and T2 lesion load, have revealed 
discordant findings (van der Werf et al., 1998; Mainero et al., 1999). Sepulcre et 
al., found a correlation between fatigue in MS and white matter (WM) lesion 
load (Sepulcre et al., 2009). In this study, fatigue correlates with the presence of 
MS lesions in the right parieto-temporal WM, a key region for attentional 
mechanisms. This region is particularly critical for the so-called alerting network, 
but it is also a part of the orienting network. Spatial inattention has been linked 
in humans to disruption of the right superior occipitofrontal fasciculus, lesions of 
which correlated with the presence of fatigue in Sepulcre’s study. That also 
showed an association between fatigue and Other deep WM of the left frontal 
lobe, including the anterior corpus callosum. 
More recently, morphometric MRI has shown a correlation between fatigue and 
white and grey matter volume (Tedeschi et al., 2007), partially supporting other 
findings which suggested a link between fatigue and dysfunction of deep grey 
matter regions (Inglese et al., 2007). The results of Tedeschi et al. suggest that 
 21 
fatigue is correlated with diffuse CNS involvement even in MS patients with low 
disability, as patients with high-fatigue showed significantly higher lesion load, 
and WM, grey matter (GM) atrophy than patients with low-fatigue. Although 
patients with higher FSS had higher lesion load, the univariate and multivariate 
statistical analysis did not identify lesion load as a risk factor of fatigue. 
Conversely,  data suggest that fatigue, independent of disability, is significantly 
related to a destructive pathological process involving both WM and GM (as 
measured by WM and GW atrophy). Previous MRI studies on smaller patients' 
samples have unsuccessfully attempted to correlate fatigue and MRI measures 
such as T2 lesion load, brain atrophy, monthly gadolinium enhancing lesions 
and magnetization transfer ratios (Van den Werf et al., 1998; Bakshi et al., 
1999; Mainero et al., 1999; Codella et al., 2002). Recently, in a longitudinal 
study performed in a cohort of 134 patients with MS (Marrie et al., 2005) no 
correlation was found between fatigue (measured by the Sickness Impact 
Profile's Sleep and Rest Scale) and brain atrophy at baseline. However, there 
was a significant association between worsening fatigue during the initial 2 
years and progressive brain atrophy over the next 6 years, when comparing 
patients who showed an increased fatigue with those who showed a decreased 
fatigue. 
Other imaging studies have hypothesized that fatigue is related to damage of 
specific white matter pathways and cortical areas in the frontal and parietal 
regions (Sepulcre et al., 2009). In GM analysis, the authors found that atrophy 
of areas of the left superior frontal gyrus and both middle frontal gyri correlated 
with the presence of fatigue. As the areas in the left hemisphere are closely 
related to the WM regions where more lesions are located, their atrophy could 
be construed as indicating retrograde degeneration of neurons projecting 
through the affected WM region or transynaptic degeneration after axon 
transection in the WM lesions. Moreover these results suggest the presence of 
an atrophy threshold for the generation of fatigue, because of founding an 
increasing association between fatigue score and cortical volume going from 
the healthy group to non-fatigue MS patients and from these to fatigued MS 
patients. 
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Roelcke et al. suggested a possible role of the striatum–thalamus–frontal cortex 
pathway in the genesis of fatigue, suggested by the finding of a reduced 
metabolic activity of the putamen, the lateral and medial prefrontal cortex, the 
premotor cortex and the right supplementary motor area in severely fatigued 
MS patients (Roelcke et al. 1997). Calabrese et al. confirmed and extended 
these observations, and further indicated that a pathological process affecting 
the striatum–thalamus–frontal cortex pathway occurs in fatigued RR MS. 
Indeed, while a diffuse frontal-temporal cortical thinning characterizes patients 
with RR MS compared to healthy subjects, a more pronounced thinning of the 
cortical areas involved in the striatum–thalamus–frontal cortex pathway 
distinguishes fatigued RR MS patients (Calabrese et al., 2010) (FIG.4) from 
non-fatigue MS patients. 
 
 
The main finding of Andreasen et al. was that primarily fatigued MS patients 
have regional atrophy involving functionally related grey matter structures and 
nearby white matter. Principal areas were the frontal and parietal lobes and the 
basal ganglia. The two largest atrophy clusters involved grey and white matter 
in/nearby the dorsolateral prefrontal cortex and posterior parts of the parietal 
lobe (FIG.5).  
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Figure 5. Brain atrophy in deep grey matter structures. 
 
Also other clusters involved the limbic lobe, the anterior cingulate and mesial 
aspect of the superior frontal gyrus (Andreasen et al., 2010). These findings 
demonstrated a concordance between central muscle activation impairment and 
atrophy within areas of the motor circuit among primary fatigued patients, 
involving the primary motor cortex and premotor area. This may suggest that 
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the consequences of regional atrophy, with respect to physical disability, are 
reduced because of functionally compensatory activity, and that the same 
mechanism induces increased neuronal work and thereby triggers the 
perception of motor fatigue. Also, regional atrophy in primary fatigued patients 
compared to healthy controls involved the thalamic ventral anterior and ventral 
lateral nuclei which are involved in motor planning and action execution 
(Draganski et al., 2008). In non-fatigued patients regional atrophy was found 
within the thalamus compared to healthy controls. In all cases, nine clusters of 
atrophy were identified, and several appeared within the motor network from 
cerebellum and rostral to that. The involvement of the anterior cingulate, medial 
frontal cortex and striatum may imply that motivational disturbances play a role. 
Lesions within these areas have been correlated to lack of spontaneity, apathy 
and akinetic mutism. The recent finding of regional atrophy affecting cortex and 
adjacent white matter and the involvement of the basal ganglia strongly support 
the cortico-subcortical-circuit interruption as a pathological substrate of primary 
fatigue in MS. This is emphasized by the convergence of central motor 
activation impairment and atrophy within areas of the motor circuit in primary 
fatigued patients including premotor cortex and primary motor cortex. 
Studies of functional MRI have shown widespread cortical activation during a 
simple motor task in RR, primary progressive (PP) and secondary progressive 
(SP) MS (Filippi et al., 2002). MS patients show greater pre-fatigue activation of 
brain regions involved in motor responses (precentral gyrus, cerebellum, insula 
and cingulated gyrus), compared to healthy controls. Increase in cortical 
activation has been interpreted as an adaptive response to dysfunction of motor 
pathways (FIG.6). 
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Figure 6. Activated areas in non fatigue MS patients (on the left) and fatigue MS patient (on the 
right). From Filippi et al., 2022 
 
Fatigue in MS may be a result of cortico-subcortical (thalamus and basal 
ganglia) interactions during motor tasks planning and execution. Moreover, an 
increase in activation of anterior cingulated cortex, involved in attentional task 
and executive functions, has been reported in MS patients affected by fatigue, 
probably as a compensatory mechanism (Filippi et al., 2002). In addition, the 
some group with Rocca et al., investigated temporary fatigue in MS patients 
under weekly treatment with IFNβ-1a (Rocca et al., 2007). The authors showed 
a progressive reduction of the activation of the primary Sensory Motor Cortex 
during follow-up, independently of the presence/absence of fatigue, in the two 
groups of patients. The within-group analysis of fMRI changes in this study also 
showed different patterns of brain recruitment in MS patients with and without 
reversible fatigue. In particular, during tasks, MS patients with reversible fatigue 
after IFNβ-1a injection showed increased activations of the basal ganglia 
(thalami and lenticular nuclei). Conversely, in MS patients without reversible 
fatigue, before IFNβ-1a injection, the thalamus was more activated, as well as 
the cerebellum. Compared to MS patients with reversible fatigue, those with 
permanent fatigue tended to have an increased recruitment of the SII, 
cerebellum, and several regions in the parietal lobes. Conversely, MS patients 
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with reversible fatigue showed increased activations of the primary SMC, basal 
ganglia, thalami, SMA, CMA, and several regions located in the frontal lobes 
(FIG.7). 
 
Figure 7. Activeted areas in MS patients affected by fatigue secondary to IFNB-1° injection. From 
Rocca et al., 2007. 
 
All these studies suggest that some MS patients might have an increased 
susceptibility to fatigue, which is related to a different sensorimotor circuitry 
recruitment during the performance of motor activity. In particular, it seems 
likely that potentially fatigable MS patients tend to have a baseline 
“overactivation” of the basal ganglia, frontal lobes, and cingulum. With time, this 
“overactivation” might result in a depletion of the functional properties of these 
regions and in their inability to undergo the dynamic changes observed in MS 
patients without reversible fatigue and, as a consequence, lead to the onset of 
“chronic” fatigue. 
Lastly, cerebral metabolism studies support this findings, having demonstrated 
a reduced glucose metabolism in cortical motor and basal ganglia regions which 
correlates with fatigue severity (Roelcke et al., 1997). The authors compared 
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two MS groups, showing predominant cerebral glucose metabolism reductions 
bilaterally in a prefrontal area involving the lateral and medial prefrontal cortex 
and adjacent white matter, in the premotor cortex, putamen, and in the right 
supplementary motor area of MS fatigued patients. In addition, there was 
cerebral glucose metabolism reduction in the white matter extending from the 
rostral putamen toward the lateral head of the caudate nucleus. Fatigue severity 
scale values were inversely related to cerebral glucose metabolism in the right 
prefrontal cortex. Cerebral glucose metabolism in the cerebellar vermis and 
anterior cingulate was relatively higher in fatigued MS patients than in non-
fatigued patients. These data strengthen the hypothesis that fatigue in MS is 
associated with frontal cortex and basal ganglia dysfunction that could result 
from demyelination of the frontal white matter. 
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AIM OF THE STUDY 
Fatigue in MS is likely of central origin. MS patients with fatigue are supposed to 
have demyelinating lesions within specific brain networks involved in 
maintaining a central drive to motor neurons. As reported by previous functional 
MRI studies, fatigued MS patients show greater activation of cerebral areas and 
a greater number of brain activated areas, compared to healthy subjects and 
MS patients without fatigue. These findings are believed to reflect adaptive 
changes and brain plasticity. On the other hand, correlations between specific 
cerebral networks activation and brain atrophy support a neurodegenerative 
origin of fatigue. 
In the present study a group of mildly disabled RRMS patients with and without 
fatigue and a group of healthy subjects underwent conventional, morphometric 
and functional MRI, with the following objectives: 1) Defining the pattern of 
activated brain areas in MS patients with fatigue during the performance of a 
simple motor task at rest (primary outcome) and after a maximal effort hand-grip 
exercise 
3) Comparing the characteristics of activated areas across groups (controls, 
non-fatigued and fatigued MS subjects) 
4) Correlating brain activation patterns and brain volumes with clinical variables 
(neurological disability, fatigue severity, etc). 
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METHODS 
 
STUDY SUBJECTS’ SELECTION: 
Patients will be selected from the MS Outpatient Clinic at G. Rossi Hospital in 
Verona (Italy) according to the following inclusion criteria: 
1. diagnosis of MS according to Polman's criteria; 
2. relapsing-remitting disease course; 
3. age 18-60; 
4. EDSS=0-4.5; 
5. right-hand dominance (Edinburg Handedness Inventory score >=0.90); 
6. complaint of fatigue for at least 50% of days for more than 6 weeks; 
7. mean Fatigue Severity Scale score equal to or higher than 5.0. An 
additional group of RRMS patients without fatigue and with mean FSS 
score <5.0 – matched by age, gender, and EDSS score to patients with 
fatigue - will be selected from the same source. 
Exclusion criteria will be: 
1. motor/sensory impairment of the right upper limb which could interfere 
with f-MRI evaluation; 
2. one or more relapses in the previous year; 
3. steroids in the previous year; 
4. treatment with amantadine and/or 4-aminopyridine within the previous 
month; 
5. Montgomery and Asberg Depression Rating Scale score >=17. 
Disease-modifying therapies are permitted. A group of right-handed healthy 
subjects, age- and gender-matched to MS patients, will be used as normal 
controls. 
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Table 2. Study Inclusion Criteria. 
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CLINICAL VARIABLES AND MEASURES: 
Demographic and clinical variables will include: age; gender; education; age at 
disease onset; disease duration. 
The following scales will be administered to patients: 
Expanded Disability Status scale (EDSS): The EDSS quantifies disability in 
eight Functional Systems (FS) and allows neurologists to assign a Functional 
System Score (FSS) in each of these. The Functional Systems are: pyramidal, 
cerebellar, brainstem, sensory, bowel and bladder, visual, mental, other. EDSS 
steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 
5.0 to 9.5 are mostly defined by the impairment of ambulation. EDSS step 10 
means death due to MS (FIG.8). 
 
 
Multiple Sclerosis Functional Composite (MSFC): The MSFC is a 
multidimensional clinical outcome measure that includes quantitative tests of leg 
function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and 
cognitive function (Paced Auditory Serial Addition Test, PASAT). The MSFC is 
based on the concept that scores for these three dimensions - arm, leg, and 
cognitive function - are combined to create a single score that can be used to 
detect change over time in MS patients. This is done by creating Z- scores for 
each component of the MSFC and averaging them to create an overall 
composite score (the MSFC score). The components of the MSFC are: 
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1) Time 25-Foot Walk: The Timed 25-Foot Walk is a quantitative measure of 
lower extremity function. It is the first component of the MSFC administered at 
each visit. The patient is directed to one end of a clearly marked 25-foot course 
and is instructed to walk 25 feet as quickly as possible, but safely. The task is 
immediately administered again by having the patient walk back the same 
distance. Patients may use assistive devices when doing this task. 
2) 9-Hole Peg Test: The 9-HPT is a quantitative measure of upper extremity 
(arm and hand) function. It is the second component of the MSFC to be 
administered. Both the dominant and non-dominant hands are tested twice (two 
consecutive trials of the dominant hand, followed immediately by two 
consecutive trials of the non-dominant hand). 
3) PASAT is a measure of cognitive function that specifically assesses auditory 
information processing speed and flexibility, as well as calculation ability. The 
PASAT is presented on audiocassette tape or compact disc (CD) to control the 
rate of stimulus presentation. Single digits are presented every 3’’ and the 
patient must add each new digit to the one immediately prior to it. The test 
score is the number of correct sums given (out of 60 possible) in each trial. To 
minimize familiarity with stimulus items in clinical trials and other serial studies, 
two alternate forms have been developed; the order of these should be 
counterbalanced across testing sessions. The PASAT is the last measure of the 
MSFC that is administered at each visit. 
 
Edinburgh Handedness Inventory: it is a measurement scale used to assess 
the dominance of a person's right or left hand in everyday activities. The 
inventory can be used by an observer assessing the person, or by a person 
self-reporting hand use. The latter method tends to be less reliable due to a 
person over- attributing tasks to the dominant hand. Patients scoring equal to or 
higher than 0,90 are considered having right-hand dominance. 
 
Montgomery and Asberg Depression Rating Scale (MADRS): it is a ten-item 
diagnostic questionnaire which psychiatrists use to measure the severity of 
depressive episodes in patients with mood disorders. Patients 
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￼with a score equal to or higher than 17 were considered affected by 
depression and were not included in the study. 
 
Fatigue Severity Scale (FSS): it is a method of evaluating fatigue in MS and 
other conditions including Chronic Fatigue Immune Dysfunction Syndrome 
(CFIDS) and Systemic Lupus Erythmatosus (SLE). The FSS is designed to 
differentiate fatigue from clinical depression, since both share some symptoms. 
The FSS is a questionnaire containing nine statements that attempt to explore 
severity of fatigue symptoms. The subject is asked to read each statement and 
circle a number from 1 to 7, depending on how appropriate he/she feels the 
statement applied to him/her over the preceding week. A low value indicates 
that the statement is not very appropriate whereas a high value indicates 
agreement. Fatigue cut-off is FSS score equal or higher than 5.0. 
 
Just before MRI scans patients will be evaluated with finger tapping rate. The 
subjects are asked to put their hands on the table in the prone position, with 
fingers approximately 1 cm apart from each other. They then lift their fingers 
(except thumbs) and then tap the table in the following order: little, ring, middle, 
and index finger. They are asked to perform this movement as fast as they can 
for one minute. Rate will be obtained dividing the numbers of tapping by 60 
seconds (n°/s). 
 
IMAGING EVALUATIONS: 
 
Functional MRI Acquisition: 
Functional images will be acquired on a 1.5 T MR scanner (Symphony, 
Siemens, Erlangen, Germany) equipped with EPI capability and a standard 
transient/receive (TR) head coil and foam cushions to minimize head 
movement. The subject’s head will be stabilized with adjustable padded 
restraints on both sides. Study subjects will be instructed to remain as still as 
possible throughout the experiment. Functional MRI scanning will be conducted 
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with a T2-weighted echo planar imaging (EPI) sequence (36 slices, slice 
thickness 3 mm); In the protocol, 110 volumes will be acquired, alternating five 
activation and five control cycles (rest), resulting in a 5 min EPI recording. 
Two different conditions will be used: 
1) Resting State – low-frequency BOLD fluctuations (LFBFs) fMRI 
2) Simple task: finger-tapping stimulation 
The fMRI paradigm used will be a block design sequence (BABAB), for the 
motor task, with periods of a 30 seconds of rest (B) and periods of 30-seconds 
visually cued hand movement (A). The sequence (BABAB) was repeated before 
and after the fatigue protocol. Fatigue protocol consists of a maximal effort 
hand-grip exercise sustained for 3 minutes. Patients will be scanned while 
performing movements of flexion-extension of the last four fingers of the right 
hand. Patients will be instructed to avoid mirror-movements during MRI 
acquisitions and will be asked to keep their eyes closed during MRI. 
Body temperature will be assessed before f-MRI evaluation 
 
Structural MRI acquisition: 
Conventional images will be acquired using turbo spin-echo proton density- and 
T2-weighted sequences on the axial plane and spin-echo T1-weighted images 
(sagittal slice orientation). Brain tissues volumes will be calculated with 
SIENAX, tool in FSL, obtaining a total brain volume (TBV), grey matter (GM) 
volume and white matter (WM) volume. 
 
Clinical and structural MRI measures analysis: 
Demographic, clinical and radiological variables differences between fatigued 
and non-fatigued MS patients will be analyzed with t test and Kruskal-wallis test. 
Correlations between clinical variables, radiological measures and functional 
scale scores will be analyzed with Spearman’s correlation coefficient. 
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Functional MRI analysis: 
Image post-processing will be performed on an independent computer 
workstation. f-MRI data will be analyzed using the Brainvoyager software and 
FSL software. First, images will be realigned to the first one to correct for 
subject motion, spatially normalized into the stereotaxic space of Talairach and 
Tournoux (1988), and smoothed wit a 10-mm, 3D Gaussian filter. Variations in 
BOLD contrast associated with motor task will be assessed on a pixel-by-pixel 
basis with general linear model and the theory of Gaussian fields. Significant 
hemodynamic changes for each contrast will be assessed using t statistical 
parametric maps. A random-effect analysis will be performed, for comparison 
between groups; the paired t-test will be used to assess activation differences 
within individual groups, while ANOVA and t test will be used for comparison 
across groups. The correlation between BOLD changes and FSS scores and 
brain volumes will be also evaluated with a linear regression analysis. 
Resting state analysis was performed with MELODIC, tool of FSL. MELODIC 
3.0 uses Independent Component Analysis to decompose a single or multiple 
4D data sets into different spatial and temporal components. For ICA group 
analysis, MELODIC uses either Tensorial Independent Component Analysis 
(TICA, where data is decomposed into spatial maps, time courses and 
subject/session modes) or a simpler temporal concatenation approach. 
MELODIC can pick out different activation and artefactual components without 
any explicit time series model being specified. 
 
Structural MRI analysis: 
Brain tissue volume, normalised for subject head size, was estimated with 
SIENAX (Smith 2001, Smith 2002), part of FSL (Smith 2004). SIENAX starts by 
extracting brain and skull images from the single whole-head input data (Smith 
2002). The brain image is then affine-registered to MNI152 space (Jenkinson 
2001, Jenkinson 2002) (using the skull image to determine the registration 
scaling); this is primarily in order to obtain the volumetric scaling factor, to be 
used as a normalisation for head size. Next, tissue-type segmentation with 
partial volume estimation is carried out (Zhang 2001) in order to calculate total 
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volume of brain tissue (including separate estimates of volumes of grey matter, 
white matter, peripheral grey matter and ventricular CSF). 
 
SAMPLE SIZE DETERMINATION: 
Very few studies have focused on sample size calculation in the f-MRI research 
field. 
We calculated sample size according to the functional MRI parameters 
considered as the primary outcome of the study (i.e. pattern of activated brain 
areas in MS patients with fatigue during the performance of a simple motor 
task). We used the same assumptions of a previous study which focused on 
power analysis for within-group f-MRI experiments in a single population, using 
a verbal working memory task to obtain estimates of percent signal change and 
of intra-subject and inter-subjects variability in order to generate power curves. 
These estimates were used in simulation experiments (somato-sensory 
stimulation) showing a good correspondence with the results of the cognitive 
task experiment (JE Desmond et al., 2002). 
In order to detect a signal change before and after motor task performance of 
approximately 0.5% and a spatial smoothing at FWHM of 5 mm, at least 12 
patients are needed to insure a 80% power with alfa=0.05 at the single voxel 
level. 
 
STATISTICAL ANALYSIS 
Brain f-MRI was analysed with Brainvoyager QX 2.0 AND FSL. Statistical 
analysis was conducted with SPSS 16.0. 
Analysis between pre and post application of “fatigue protocol” were conducted 
with paired t-Test and Wilcoxon Rank Test. Analysis between groups were 
conducted with unpaired t-test, Mann-Whitney Test and ANOVA. 
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RESULTS 
Sample description. 
Twelve MS patients (6 with fatigue and 6 without fatigue) were selected from 
the database of Outpatients Clinic in Policlinico Hospital in Verona. Tree healthy 
subjects were enrolled in the study. In table are shown demographic and clinical 
data (TAB.3). 
 
Table 2. Summary of demographical and clinical variables of study groups. 
 
The two groups of patients, MS with fatigue and MS without fatigue, did not 
differ fin terms of demographical variables and disability, expressed both with 
EDSS score and MSFC and its sub-items (25FWT, 9HPT and PASAT) (TAB.4). 
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MRI EVALUATION 
MORPHOLOGICAL EVALUATION 
Analysis of total brain, grey matter and white matter volume were conducted 
running Sienax on T1 3D images. This analysis was conducted on MS patients, 
with and without fatigue, and on healthy subjects. 
The results of the analysis are shown in TAB.5, while FIG.9 shows 
segmentation process on patients. 
 
 
 
Table 3. Structural variables and statistical analysis of study groups. 
NON-FATIGUE VS 
FATIGUE MS 
MS PATIENTS VS 
HEALTHY 
SUBJECTS 
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Figura 9. Segmentation processes in SIENAX analysis. 
 
The between-group analysis on fatigued versus not-fatigued MS patients did not 
reveal any differences in volumes (TAB.). The between-group analysis on MS 
patients versus healthy subjects showed a significantly higher total brain 
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volume, grey matter volume and white matter volume in controls compared to 
MS patients (TAB.). 
There was no correlation between FSS score and brain volumes. 
 
FUNCTIONAL EVALUATION 
In order to reduce artefact and noise-related signal components, a series of 
mathematical operations is typically performed prior to statistical data analysis. 
The most essential steps of these preprocessing operations are: 
1) Removal of global signal fluctuations 
2) Slice scan timing correction 
3) Head motion detection and correction (FIG.10) 
4) Spatial and temporal smoothing of the data 
5) Removal of linear and non-linear trends in voxel time courses 
 
Figure 10. Head motion detection and correction. 
 
To guarantee a good alignment result in any situation, the coregistration 
(FIG.11) process has been split into two main stages: 
1) Initial alignment (IA) 
2) Fine-tuning alignment (FA) 
The goal of the initial alignment step is to bring the functional and anatomical 
data sets in close proximity from a potentially very different starting point. If, for 
example, the functional data is recorded in the axial plane while the anatomical 
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data is recorded in the sagittal plane, the initial alignment should bring them at 
least in the same global orientation, i.e. by using large rotations and translation 
values. The fine-tuning alignment step on the other hand assumes that the two 
data sets are already pretty close to each other, which may allow iterative 
minimization techniques to do an automatic fine adjustment of the alignment in 
a similar way as during 3D motion correction. 
 
Figure 11. Coregistration of functional scanning on anatomical images. 
 
In the original definition (Talairach & Tournaux, 1988), the midpoint of the 
anterior commissure (AC) is located first, serving as the origin of Talairach 
space. The brain is then rotated around the new origin (AC) so that the posterior 
commissure (PC) appears in the same axial plane as the anterior commissure. 
The connection of AC and PC in the middle of the brain forms the y-axis of the 
Talairach coordinate system. The x-axis runs from the left to the right 
hemisphere through AC. The z-axis runs from the inferior part of the brain to the 
superior part through AC. In order to further specify the x and z-axes, a y-z 
plane is rotated around the y (AC-PC) axis until it separates the left and right 
hemisphere (mid-sagittal plane). This completes the first part of Talairach 
transformation, often called AC-PC transformation. The obtained AC-PC space 
is attractive for individual clinical applications, especially presurgical mapping 
and neuronaviagation since it keeps the original size of the brain intact while 
providing a common orientation for each brain.  
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For a full Talairach transformation, a cuboid in AC-PC space is defined that runs 
parallel to the three axes defined in the first step enclosing precisely the cortex. 
This cuboid or bounding box requires specification of additional landmarks 
specifying the borders of the cerebrum. The bounding box is sub-divided by 
several sub-planes. The midsagittal y-z plane separates two sub-cuboids 
containing the left and right hemisphere, respectively. An axial (x-y) plane 
through the origin separates two sub-cuboids containing the space below and 
above the AC-PC plane. Two coronal (x-z) planes, one running through AC and 
one running through PC, separate three sub-cuboids; the first contains the 
anterior portion of the brain anterior to the AC, the second contains the space 
between AC and PC and the third contains the space posterior to PC. These 
planes separate 12 sub-cuboids. In a final Talairach transformation step, each 
of the 12 sub-cuboids is expanded or shrunken linearly to match the size of the 
corresponding sub-cuboid of the standard Talairach brain. To reference any 
point in the brain, x, y, z coordinates are specified in millimeters of Talairach 
space. Talairach & Tournoux (1988) also defined the proportional grid to 
reference points within the defined cuboids (Fig.12). 
 
Figure 12. Talairach space coregistration. 
 
For each activated area number of voxel was calculated and used for statistical 
purposes. 
Analysis of functional data before application of fatigue protocol showed 
activation of left sensorimotor cortex (L-SMC), bilateral supplementary motor 
area (BIL-SMA), left and right cerebellum in both fatigue and non fatigue MS 
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patients. Non fatigue patients activated also right sensorimotor area (R-SMA) 
and left inferior frontal gyrus (L-IFG). After fatigue protocol the same pattern of 
activation was observed, with the appearance of activation of R-SMA in fatigued 
patients. 
Areas activated during simple motor task are shown in Tab. 5 
 
Table 4. Activated area in patients groups before and after fatigue protocol. 
 
Within-group analysis in fatigued MS patients before and after fatigue protocol 
did not shown any statistical difference. Within-group analysis in non fatigue MS 
patients showed a significant difference in activation in left somatosensory 
motor area (p=0,028) (TAB.6). 
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Table 5. Within-group analysis of functional data. 
 
 
Between-group analysis (fatigue MS versus non fatigue MS) showed no 
difference before and after fatigue protocol (Tab.7). 
 
Table 6. Between-group analysis of functional data. 
 
 
 
No correlation between FSS score and activated areas before and after fatigue 
was observed. 
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Resting state analysis showed no differences in baseline activated network 
between the two groups and before/after application of fatigue protocol. 
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DISCUSSION 
The present study has not been able to detect any correlation between MRI and 
clinical variable expressed as EDSS and MSFC score. These findings agree 
with some study in the literature (van der Werf et al., 1998; Mainero et al., 1999) 
where no correlation was found between fatigue and both standard MRI 
variables (lesion load) and structural variables (brain tissue volume). However, 
Tedeschi and coworkers have shown a correlation between fatigue and white 
and grey matter volume in a large sample of MS patients (222 patients), 
although there were few subjects in non fatigue group (n=25) compared to 
fatigue MS (n=197) (Tedeschi et al., 2007). Our inability to reach the same 
finding may be due to a lack in power of the present study because of the low 
number of patients in each group (fatigue MS=6; non fatigue MS=6). Tedeschi 
et al. suggested that fatigue is correlated to diffuse CNS involvement even in 
MS patients with low disability, as patients with high-fatigue showed significantly 
higher WM and grey matter (GM) atrophy than patients with low-fatigue. 
Furthermore, they suggest that in MS, independent of disability, WM and GM 
atrophy is a risk factor to have fatigue. 
Regarding functional data analysis, our MS patients showed greater activation 
during a single motor task in bilateral sensory-motor cortex, bilateral 
supplementary motor area, bilateral cerebellum and left inferior frontal gyrus. 
After application of fatigue protocol the same areas were detected with the only 
exception of fatigue group, in which the contralateral motor cortex was silent 
before fatigue protocol, while it was recruited after fatigue protocol. This results 
confirm data collected from Filippi et al. in 2002 using a similar study protocol 
(Filippi et al., 2002). To date this pattern of brain activation was still waiting for 
confirmational data. Notwithstanding, our between-group analysis, both before 
and after fatigue, did not reply Filippi et al. data, which showed significant 
differences of activation in these areas. Probably also in this case our sample is 
to small to detect differences in activated and deactivated neurons. However, 
we can confirm that in fatigue origin process numerous structures are involved. 
Compared to healthy subjects, MS patients, even disregarding the presence of 
fatigue, need the cooperation of more network to reach the same task. Indeed, 
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MS patients required a greater activation in controlateral sensorymotor area and 
cerebellum. This can be probably explained by an alteration of cortical and 
subcortical network involved in motor task and perception functions, requiring  
activation of contralateral areas in both hemispheres. 
Within-group analysis in fatigue patients did not find any change before and 
after application of the “fatigue protocol”. However, in non fatigue-MS group we 
found a significant decrease in activation of left sensory-motor area after the 
“fatigue protocol” (p= 0.028), which has no clear explanation and needs to be 
confirmed in a larger sample. As pure speculation, we may interpret this results 
as reflection of loss of the central drive in L-SMC neurons. In the hypothesis 
that fatigue in MS has a central and supraspinal origin, decrease in activation of 
the L-SMC during a right-handed task explain reduction in central ability to 
sustain prolonged activation in fatigued conditions. 
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CONCLUSIONI 
Fatigue in MS patients is not related to demographic and clinical variables 
expression of disability (EDSS, MSFC and related sub-items). 
MS patients during a single motor task showed a predominant activation of 
bilateral sensory-motor cortex, bilateral supplementary motor area, bilateral 
cerebellum and left inferior frontal gyrus. 
Our analysis showed no differences between patients groups in terms of 
activation volumes. 
In the fatigue-MS group we did not find any change before and after application 
of the “fatigue protocol”. In the non fatigue-MS group we found a significant 
decrease in activation of left sensory-motor area after the “fatigue protocol” (p= 
0.028), which has no clear explanation and needs to be confirmed in a larger 
sample.
 50 
BIBLIOGRAFIA 
 
1. Amato MP, Ponziani G. A prospective study on the prognosis of multiple 
sclerosis. Neurol Sci 2000; 21 (Suppl): 831-838. 
2. Andreasen AK, Jakobsen J, Soerensen L, Andersen H, Petersen T, 
Bjarkam CR, Ahdidan J. Regional brain atrophy in primary fatigued 
patients with multiple sclerosis. Neuroimage. 2010 Apr 1;50(2):608-15. 
3. Archibald, C.J., P.J. McGrath, and P.G. Ritvo et al. 1994. Pain 
prevalence, severity, and impact in a clinic sample of multiple sclerosis 
patients. Pain 58: 89-93. 
4. Arnold DL. Magnetic resonance spectroscopy: imaging axonal damage in 
MS. J Neuroimmunol 1999; 98:2-6. 
5. Bakshi R, Miletich RS, Henschel K, Shaikh ZA, Janardan V, Wasay M, et 
al. Fatigue in multiple sclerosis: cross-sectional correlation with brain 
MRI findings in 71 patients. Neurology 1999;53:1151–3. 
6. Bates, D.W., W. Schmitt, and D. Buchwald et al. 1993. Prevalence of 
fatigue and chronic fatigue in a primary care practice. Arch Intern Med 
153: 2759-65. 
7. Beck, R.W., P.A. Cleary, and J.D. Trobe et al. 1993. The effect of 
corticosteroids for acute optic neuritis on the subsequent development of 
multiple sclerosis. N Engl J Med 329: 1764-69. 
8. Behm DG, Whittle J, Button D, and Power K. Intermuscle differences in 
activation. Muscle Nerve 25: 236-243, 2002 
9. Bigland-Ritchie B, Furbush F, and Woods JJ. Fatigue of intermittent 
submaximal voluntary contractions: central and peripheral factors. J Appl 
Physiol 61: 421-429, 1986 
10. Bigland-Ritchie B, Johansson R, Lippold OC, Smith S, and Woods JJ. 
Changes in motoneurone firing rates during sustained maximal voluntary 
contractions. J Physiol 340: 335-346, 1983. 
11. Bot JC, Barkhof F, Lycklama à Nijeholt G, van Schaardenburg D, 
Voskuyl AE, Ader HJ, Pijnenburg JA, Polman CH, Uitdehaag BM, 
Vermeulen EG, Castelijns JA. Differentiation of multiple sclerosis from 
other inflammatory disorders and cerebrovascular disease: value of 
spinal MR imaging. Radiology. 2002 Apr;223(1):46-56. 
12. Bot JC, Blezer EL, Kamphorst W, Lycklama A Nijeholt GJ, Ader HJ, 
Castelijns JA, Ig KN, Bergers E, Ravid R, Polman C, Barkhof F. 
Radiology. 2004 Nov;233(2):531-40. 
13. Brex PA, O'Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, 
Miller DH. Multisequence MRI in clinically isolated syndromes and the 
early development of MS. Neurology. 1999 Oct 12;53(6):1184-90. 
 51 
14. Buchwald, D., J.L. Sullivan, and A.L. Komaroff. 1987. Frequency of 
chronic active Epstein-Barr virus infection in a general medical practice. 
JAMA 257: 2303-7. 
15. Calabrese M, Rinaldi F, Grossi P, Mattisi I, Bernardi V, Favaretto A, 
Perini P, Gallo P. Basal ganglia and frontal/parietal cortical atrophy is 
associated with fatigue in relapsing-remitting multiple sclerosis. Mult 
Scler. 2010 Oct;16(10):1220-8. Epub 2010 Jul 29. 
16. Charcot JM. Leçon sur les maladies du sistème nerveux faites a la 
Salpétière. Paris: Delahaye A, Lecronier E. Progrès Médicale, 1872. 
17. Ciccarelli O, Werring DJ, Wheeler-Kingshott CAM et al. Investigation of 
multiple sclerosis normal-appearing brain using diffusion tensor MRI with 
clinical correlations. Neurology 2001; 56:926-933. 
18. Clark, C.M., J.A. Fleming, and D. Li et al. 1992. Sleep disturbance, 
depression, and lesion site in patients with multiple sclerosis. Arch 
Neurol 49: 641-43. 
19. Codella M, Rocca MA, Colombo B, Martinelli-Boneschi F, Comi G, Filippi 
M. Cerebral grey matter pathology and fatigue in patients with multiple 
sclerosis: a preliminary study. J Neurol Sci 2002;194:71–4. 
20. Comparison of MRI criteria at first presentation to predict conversion to 
clinically definite multiple sclerosis. Barkhof F, Filippi M, Miller DH, 
Scheltens P, Campi A, Polman CH, Comi G, Adèr HJ, Losseff N, Valk J. 
Brain. 1997 Nov;120 ( Pt 11):2059-69. 
21. Compston A, Alasdair A. Multiple sclerosis. Lancet 2002; 359:1221-1231. 
22. Confavreux C, Compston A. The natural history of multiple sclerosis. In: 
Compston A, editor. “McAlpine’s multiple sclerosis. 4th edn.” London: 
Chirchill Livingstone Elsevier, 2006. p. 183-272. 
23. Confavreux C, Vukusic S, Moreau T et al. Relapses and progression of 
disability in multiple sclerosis. N Engl J Med 2000; 343:1430-1438. 
24. Confavreux C, Vukusic S. Age at disability milestone in multiple 
sclerosis. Brain 2006; 129:595-605. 
25. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying 
concept. Brain 2006; 129:606-616. 
26. Confavreux C. L’histoire naturelle de la scérose en plaques. Etude par 
informatique de 349 observations. Thèse de Médicine. Lyon: Université 
Claude Bernard; 1977. p.184. 
27. Cookfair, D., J. Fischer, R.A. Rudick, and the MSCRG. 1997. Fatigue 
severity in low disability MS patients participating in a phase III trial of 
Avonex (INF-1a) for relapsing multiple sclerosis. Neurology 48 
(supplement 2): A173. 
28. Dalton CM, Brex PA, Miszkiel KA, Fernando K, MacManus DG, Plant 
GT, Thompson AJ, Miller DH. Spinal cord MRI in clinically isolated optic 
neuritis. J Neurol Neurosurg Psychiatry. 2003 Nov;74(11):1577-80. 
 52 
29. Davis, F.A., and S. Jacobson. 1971. Altered thermal sensitivity of injured 
and demyelinated nerve. J Neurol, Neurosurgery, Psychiatry: 34: 551-61. 
30. Desmond JE, Glover GH. Estimating sample size in functional MRI 
(fMRI) neuroimaging studies: statistical power analysis. J Neurosc 
Methods 2002; 118:115-128. 
31. Enoka RM and Stuart DG. Neurobiology of muscle fatigue. J Appl 
Physiol 72: 1631-1648, 1992 
32. Evangelou N, Esiri MM, Smith S et al. Quantitative pathological evidence 
for axonal loss in normal appearing white matter in multiple sclerosis. 
Ann Neurol 2000; 47:391-395. 
33. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, 
Lechner H. Criteria for an increased specificity of MRI interpretation in 
elderly subjects with suspected multiple sclerosis. Neurology. 1988 
Dec;38(12):1822-5. Magnetic resonance imaging in the assessment of 
disease activity in multiple sclerosis. 
34. Ferini-Strambi, L., M. Filippi, and V. Martinelli et al. 1994. Nocturnal sleep 
study in multiple sclerosis: correlations with clinical and brain magnetic 
resonance image findings. J Neurol Sci 125: 194-97. 
35. Filippi M, Bozzali M, Rovaris M et al. Evidence for widespread axonal 
damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 
126:433-437. 
36. Filippi M, Falini A, Arnold DL, Fazekas F, Gonen O, Simon JH, Dousset 
V, Savoiardo M, Wolinsky JS; White Matter Study Group. Magnetic 
resonance techniques for the in vivo assessment of multiple sclerosis 
pathology: consensus report of the white matter study group. J Magn 
Reson Imaging. 2005 Jun;21(6):669-75 
37. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of 
fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994;21:9–
14. 
38. Fitch S and McComas A. Influence of human muscle length on fatigue. J 
Physiol 362: 205-213, 1985 
39. Foglio, K., E. Clini, and D. Facchetti. 1994. Respiratory muscle function 
and exercise capacity in MS. European Resp Journal 7: 23-28. 
40. Freal, J.F., G.H. Kraft, and J.K. Coryell. 1984. Symptomatic fatigue in 
MS. Arch Phys Med Rehabil 65: 135-38. 
41. Garland SJ and Kaufman MP. Role of muscle afferents in the inhibition of 
motoneurons during fatigue. Adv Exp Med Biol 384: 271-278, 1995. 
42. Garland SJ. Role of small diameter afferents in reflex inhibition during 
human muscle fatigue. J Physiol 435: 547-558, 1991. 
43. Granieri E, Malagù S, Casetta I et al. Multiple sclerosis in Italy. A 
reappraisal of incidence and prevalence in Ferrara. Arch Neurol 1996; 
53:793-798. 
 53 
44. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked 
potentials in identifying clinically silent lesions in patients with suspected 
multiple sclerosis (an evidence-based review): Report of the Quality 
Standards Subcommittee of the American Academy of Neurology. 
Neurology. 2000 May 9;54(9):1720-5. 
45. Hunter SK and Enoka RM. Changes in muscle activation can prolong the 
endurance time of a submaximal isometric contraction in humans. J Appl 
Physiol 94: 108-118, 2003. 
46. Immunoglobulin abnormalities in spinal fluid in multiple sclerosis. Link H, 
Möller E, Muller R, Norrby E, Olsson JE, Stendahl L, Tibbling G. Acta 
Neurol Scand Suppl. 1977;63:173-91. 
47. Inglese M, Park SJ, Johnson G, Babb JS, Miles L, Jaggi H, Herbert J, 
Grossman RI. Deep gray matter perfusion in multiple sclerosis: dynamic 
susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch 
Neurol 2007;64:196–202. 
48. Iuliano G. Prevalence of multiple sclerosis in Salerno, Italy: preliminary 
data in a study on general practitioners. Italian J of Neurological 
Sciences 1999; 20(Suppl 4): S186. 
49. Jenkinson M and Smith SM. A global optimisation method for robust 
affine registration of brain images. Medical Image Analysis, 5(2):143-156, 
June 2001.  
50. Jenkinson M, Bannister PR, Brady JM, and Smith SM. Improved 
optimisation for the robust and accurate linear registration and motion 
correction of brain images. NeuroImage, 17(2):825-841, 2002.  
51. Joffe, R.T., G.P. Lippert, and T.A. Gray et al. 1987. Mood disorder and 
multiple sclerosis. Arch Neurol 44: 376-78. 
52. Kanehisa H, Ikegawa S, and Fukunaga T. Force-velocity relationships 
and fatiguability of strength and endurance-trained subjects. Int J Sports 
Med 18: 106-112, 1997. 
53. Kent-Braun, J., K.R. Sharma, and M.W. Weiner et al. 1994. Effects of 
exercise on muscle activation and metabolism in MS. Muscle & Nerve 
17: 1162-69. 
54. Kernell D. Synaptic conductance changes and the repetitive impulse 
discharge of spinal motoneurones. Brain Res 15: 291-294, 1969 
55. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus 
DG, McDonald WI, Miller DH. Spinal cord MRI using multi-array coils and 
fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993 
Dec;43(12):2632-7. 
56. Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S. Origin of 
fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural 
Repair 2008;22:91–100. 
57. Kroenke, K., D.R. Wood, and A.D. Mangelsdorff et al. 1988. Chronic 
fatigue in primary care. JAMA 260: 929-34. 
 54 
58. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity 
scale. Application to patients with multiple sclerosis and systemic lupus 
erythematosus. Arch Neurol 1989;46:1121–3. 
59. Lee M, Gandevia S, Carroll T. Cortical voluntary activation can be 
reliably measured in human wrist extensors using transcranial magnetic 
stimulation. Clin Neurophysiol 2008;119:1130–8. 
60. Leocani L, Colombo B, Magnani G, Martinelli-Boneschi F, Cursi M, Rossi 
P, Martinelli V, Comi G. Fatigue in multiple sclerosis is associated with 
abnormal cortical activation to voluntary movement – EEG evidence. 
Neuroimage 2001;13:1186–92. 
61. Liepert J, Mingers D, Heesen C, Baumer T, Weiller C. Motor cortex 
excitability and fatigue in multiple sclerosis: a transcranial magnetic 
stimulation study. Mult Scler 2005;11:316–21. 
62. Löscher WN and Nordlund MM. Central fatigue and motor cortical 
excitability during repeated shortening and lengthening actions. Muscle 
Nerve 25: 864-872, 2002 
63. Löscher WN, Cresswell AG, and Thorstensson A. Central fatigue during 
a long-lasting submaximal contraction of the triceps surae. Exp Brain 
Res 108: 305-314, 1996 
64. Losseff NA, Wang L, Lai HM et al. Progressive cerebral atrophy in 
multiple sclerosis. A serial MRI study. Brain 1996a; 119:2009-2019. 
65. Lublin FL, Reingold SC. The National Multiple Sclerosis Society USA 
Advisor Committee on Clinical Trials of New Agents in multiple sclerosis. 
Defining the clinical course of multiple sclerosis: results of an 
international survey. Neurology 1996; 46:907-911. 
66. Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, 
Barkhof F. Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2003 
Sep;2(9):555-62 
67. Macefield G, Hagbarth KE, Gorman R, Gandevia SC, and Burke D. 
Decline in spindle support to alpha-motoneurones during sustained 
voluntary contractions. J Physiol 440: 497-512, 1991 
68. Maddestra M, Sabbatini S, Paci F et al. Epidemiological survay of 
multiple sclerosis in the province of Terni. Neuroepidemiology 1998; 
17:54. 
69. Maeder R. Does the history of multiple sclerosis go back as far as the 
14th century? Acta Neurol Scandinav 1979; 60:189-192. 
70. Mainero C, Faroni J, Gasperini C, Filippi M, Giugni E, Ciccarelli O, et al. 
Fatigue and magnetic resonance imaging activity in multiple sclerosis. J 
Neurol 1999;246:454–8. 
71. Malatesta G, Gabriele A, Macor S et al. Diffusion of multiple sclerosis in 
two italian provinces, Chieti-Pescara. Italian Journal of Neurological 
Sciences 1991; 12(Suppl. 5):83. 
 55 
72. Marrie RA, Fisher E, Miller DM, Lee J, Rudick RA. Association of fatigue 
and brain atrophy in multiple sclerosis. J Neurol Sci 2005;228:161–6. 
73. Mayr WT, Pittock SJ, McClelland RL et al. Incidence and prevalence of 
multiple sclerosis in Olmsted Country, Minnesota, 1985-2000. Neurology 
2003; 61:1373-1377. 
74. McAlpine D, Compston ND. Some aspects of natural history of 
disseminated sclerosis: incidence, course and prognosis; factors 
affecting onset and course. Q J Med 1952; 21:135-167. 
75. McAlpine D. The benign form of multiple sclerosis. A study based on 241 
cases seen within three years of onset and followed up until the tenth 
year or more of the disease. Brain 1961; 84:186-203. 
76. McDonald WI, Compston A, Edan G et al. Recommended diagnostic 
criteria for multiple sclerosis: guidelines from the international panel on 
the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127. 
77. Meucci G, Bianchi F, Rossi G. Indagine sulla prevalenza della sclerosi 
multipla nella USL n.17 del Valdarno inferiore. In: 7th Italian Congress of 
Neuroepidemiology (Abtsract book). Tipografia Umbra Perugia, 1992; 
p.35. 
78. Miller, R.G., A.T. Green, and R.S. Moussavi et al. 1990. Excessive 
muscular fatigue in patients with spastic paraparesis. Neurology 40: 
1271-74. 
79. Minden, S.L., J. Orav, and P. Reich. 1987. Depression in multiple 
sclerosis. General Hospital Psychiatry 9: 426-34 
80. Morissey, S.P., D.H. Miller, and B.E. Kendall et al. 1993. The significance 
of brain magnetic resonance imaging abnormalities at presentation with 
clinically isolated syndromes suggestive of multiple sclerosis. Brain 116: 
135-46. 
81. Moulin, D.E., K.M. Foley, and G.C. Ebers. 1988. Pain syndromes in 
multiple sclerosis. Neurology 38: 1830-34. 
82. New diagnostic criteria for multiple sclerosis: guidelines for research 
protocols. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, 
Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. Ann 
Neurol. 1983 Mar;13(3):227-31. 
83. Olgiati, R., J.M. Burgunder, and M. Mumenthaler. 1988. Increased 
energy cost of walking in multiple sclerosis: effect of spasticity, ataxia, 
and weakness. Archives Phys Med & Rehabil 69: 846-49. 
84. Paty DW. MRI in the diagnosis of MS: a prospective study with 
comparison of clinical evaluation, evoked potentials, oligoclonal banding, 
and CT. Neurology. 1988 Jul;38(7 Suppl 2):82-3.  
85. Paty DW. Trial measures in multiple sclerosis: the use of magnetic 
resonance imaging in the evaluation of clinical trials. Can J Neurol Sci. 
1988 Aug;15(3):266-72. 
 56 
86. Plendl H, Paulus W, Roberts IG, Bötzel K, Towell A, Pitman JR, Scherg 
M, Halliday AM. The time course and location of cerebral evoked activity 
associated with the processing of colour stimuli in man. Neurosci Lett. 
1993 Feb 5;150(1):9-12. 
87. Poser CM, Brinar VV. The accuracy of prevalence rates of multiple 
sclerosis: a critical review. Neuroepidemiology 2007; 29:150-155. 
88. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple 
sclerosis in Europe. Eur J Neurol 2006; 13:700-722. 
89. Rasminsky, M. 1973. The effects of temperature on conduction in 
demyelinated single nerve fibers. Arch Neurology 28: 287-92. 
90. Rice, C.L., T.L. Volmer, and B. Bigland-Ritchie. 1992. Neuromuscular 
responses of patients with multiple sclerosis. Muscle & Nerve 15: 1123-
32. 
91. Rocca MA, Agosta F, Colombo B, Mezzapesa DM, Falini A, Comi G, 
Filippi M. fMRI changes in relapsing-remitting multiple sclerosis patients 
complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp. 2007 
May;28(5):373-82. 
92. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, 
Ammann W, et al. Reduced glucose metabolism in the frontal cortex and 
basal ganglia of multiple sclerosis patients with fatigue: a 18fluorodeoxy- 
glucose positron emission tomography study. Neurology 1997; 48: 1566–
1571. 
93. S a n d roni, P., W. Cameron, and A. Starr. 1992. Fatigue in patients with 
multiple sclerosis: motor pathway conduction and eventrelated potentials. 
A rch Neurol 49: 517-24. 
94. Sahlin K, Tonkonogi M, and Söderlund K. Energy supply and muscle 
fatigue in humans. Acta Physiol Scand 162: 261-266, 1998 
95. Schiffer, R.B., E.D. Caine, and K.A. Bamford et al. 1983. Depressive 
episodes in patients with multiple sclerosis. Amer J Psych 140: 861-65. 
96. Schumacker GA, Beebe g, Kibler RF, Kurland LT, Kurtzke JF, McDowell 
f, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL. Problems of 
experimental trials of therapy in multiple sclerosis: report by the panel on 
the evaluation of experimental trials of therapy in multiple sclerosis. Ann 
N Y Acad Sci. 1965 Mar 31;122:552–568. 
97. Schwartz CE, Coulthard Morris L, Zeng Q. Psychological correlates of 
fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996; 77:165-170. 
98. Sepulcre J, Masdeu JC, Goni J, Arrondo G, Velez de Mendizabal N, 
Bejarano B, Villoslada P. Fatigue in multiple sclerosis in associated with 
the disruption of frontal and parietal pathways. Mult Scler 2009; 15:337-
344. 
99. Sharma, K.R., J. Kent-Braun, and M.A. Mynhier et al. 1995. Evidence of 
an abnormal intramuscular component of fatigue in MS. Muscle & Nerve 
18: 1403-11. 
 57 
100. Sheean, G.L., N.M.F. Murray, and J.C. Rotwell et al. 1997. An 
electrophysiological study of the mechanism of fatigue in multiple 
sclerosis. Brain 120: 299-315. 
101. Sironi L, D’Alessandro G, Corso G, et al. Epidemiology of multiple 
sclerosis in Valle d’Aosta, Italy. Mult Scler 1997; 3:283. 
102. Smeltzer, S.C., M.H. Lavietes, and S.D. Cook. 1996. Expiratory 
training in multiple sclerosis. Arch Phys Med & Rehabil 77: 909-12. 
103. Smith SM, De Stefano N, Jenkinson M, and Matthews PM. 
Normalised accurate measurement of longitudinal brain change. Journal 
of Computer Assisted Tomography, 25(3):466-475, May/June 2001.  
104. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens 
TEJ, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney 
DE, Niazy R, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, 
and Matthews PM.    Advances in functional and structural MR image 
analysis and implementation as FSL. NeuroImage, 23(S1):208-219, 
2004.  
105. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, 
Federico A, and De Stefano N. Accurate, robust and automated 
longitudinal and cross-sectional brain change analysis. NeuroImage, 
17(1):479-489, 2002.  
106. Smith SM. Fast robust automated brain extraction. Human Brain 
Mapping, 17(3):143-155, November 2002.  
107. Steve V, Burke D, Kiernan MC. Fatigue in multiple sclerosis: 
mechanisms and menagement. Clin Neurophysiol 2010; 
doi:10.1016/j.clinph.2009.12.013. 
108. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the 
Human Brain. Thieme, New York, 1988. 
109. Taylor JL, Allen GM, Butler JE, and Gandevia SC. Supraspinal 
fatigue during intermittent maximal voluntary contractions of the human 
elbow flexors. J Appl Physiol 89: 305-313, 2000 
110. Tedeschi G, Dinacci D, Lavorgna L, Prinster A, Savettieri G, 
Quattrone A, Livrea P, Messina C, Reggio A, Servillo G, Bresciamorra V, 
Orefice G, Paciello M, Brunetti A, Paolillo A, Coniglio G, Bonavita S, Di 
Costanzo A, Bellacosa A, Valentino P, Quarantelli M, Patti F, Salemi G, 
Cammarata E, Simone I, Salvatore M, Bonavita V, Alfano B. Correlation 
between fatigue and brain atrophy and lesion load in multiple sclerosis 
patients independent of disability. J Neurol Sci 2007;263:15–9. 
111. Tesch P, Sjödin B, Thorstensson A, and Karlsson J. Muscle 
fatigue and its relation to lactate accumulation and LDH activity in man. 
Acta Physiol Scand 103: 413-420, 1978. 
112. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller 
DH, Polman CH, Stevenson VL, McDonald WI. Diagnostic criteria for 
 58 
primary progressive multiple sclerosis: a position paper. Ann Neurol. 
2000 Jun;47(6):831-5. 
113. Thorstensson A and Karlsson J. Fatiguability and fibre 
composition of human skeletal muscle. Acta Physiol Scand 98: 318-322, 
1976. 
114. Tintoré M, Rovira A, Martínez MJ, Rio J, Díaz-Villoslada P, Brieva 
L, Borrás C, Grivé E, Capellades J, Montalban X. solated demyelinating 
syndromes: comparison of different MR imaging criteria to predict 
conversion to clinically definite multiple sclerosis. AJNR Am J 
Neuroradiol. 2000 Apr;21(4):702-6 
115. Totaro R, Marini C, Cialfi A et al. Prevalence of multiple sclerosis 
in the  L’Aquila district, central Italy. J Neurol Neurosurg Psychiatry 2000; 
68:349-352. 
116. van der Werf SP, Jongen PJH, Lycklama GJ, Barkhof F, Hommes 
OR, Bleijenberg G. Fatigue in multiple sclerosis: interrelations between 
fatigue complaints, cerebral MRI abnormalities and neurological 
disability. J Neurol Sci 1998;160:174–170. 
117. Vukusic S, Confavreux C. Prognostic factors for progression of 
disability in the secondary progressive phase of multiple sclerosis. J 
Neurol Sci 2003; 206:135-137. 
118. Warnell, P. 1991. The pain experience of a multiple sclerosis 
population: a descriptive study. Axon 13: 26-28. 
119. Weinshenker BG, Bass B, Rice GP et al. The natural history of 
multiple sclerosis: a geographically based study, 1: clinical course and 
disability. Brain 1989; 112:133-146. 
120. Weinshenker BG, Bass B, Rice GP et al. The natural history of 
multiple sclerosis: a geographically based study, 2: predictive value of 
the early clinical course. Brain 1989; 112:1419-1428. 
121. Westing SH, Cresswell AG, and Thorstensson A. Muscle 
activation during maximal voluntary eccentric and concentric knee 
extension. Eur J Appl Physiol 62: 104-108, 1991 
122. Whitlock, F.A., and M.M. Siskind. 1980. Depression as a major 
symptom of multiple sclerosis. Journal of Neurol Neurosurg Psych 43: 
861-65. 
123. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. 
The clinical course of neuromyelitis optica (Devic's syndrome). 
Neurology. 1999 Sep 22;53(5):1107-14. 
124. Youl BD, Turano G, Miller DH et al. The pathophysiology  of acute 
optic neuritis. An association of gadolinium leakage with clinical and 
electrophysiology deficits. Brain 1991; 114:2437-2450. 
125. Zhang Y, Brady M, and Smith SM. Segmentation of brain MR 
images through a hidden Markov random field model and the expectation 
 59 
maximization algorithm.    IEEE Trans. on Medical Imaging, 20(1):45-57, 
2001. 
